Cardiovascular outcomes of type 2 diabetic patients treated with SGLT-2 inhibitors versus GLP-1 receptor agonists in real-life

INTRODUCTION: Sodium glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) protect type 2 diabetic (T2D) patients from cardiovascular events, but no trial has directly compared their cardiovascular effects. We aimed to address this gap using real-world d...

Descripción completa

Detalles Bibliográficos
Autores principales: Longato, Enrico, Di Camillo, Barbara, Sparacino, Giovanni, Gubian, Lorenzo, Avogaro, Angelo, Fadini, Gian Paolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Cardiovascular and Metabolic Risk
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7319723/
https://www.ncbi.nlm.nih.gov/pubmed/32591373
http://dx.doi.org/10.1136/bmjdrc-2020-001451

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7319723/
https://www.ncbi.nlm.nih.gov/pubmed/32591373
http://dx.doi.org/10.1136/bmjdrc-2020-001451

Ejemplares similares